EMA, FDA Talk Real World Evidence, Mutual Recognition, Generic Drugs
US FDA and European Medicines Agency may expand sharing beyond manufacturing inspections to clinical trials and generic drug applications.
You may also be interested in...
Postmarketing studies randomized to look at real world data sets could provide the key, Temple suggests; Amgen rep describes use of real world data to support approval of leukemia drug Blincyto.
Reliance on each other’s good manufacturing practice reports should allow EU and US regulators to better focus their limited inspection resources on drug manufacturers in other countries around the world.
The nine drug manufacturers with products selected for Medicare drug price negotiations have agreed to participate in the program. Seven of them now have pending suits challenging the Inflation Reduction Act program with Novo’s recent complaint, which objects to the aggregation of its insulin products.